MRK240906C120000
- 0.48
- +0.06+14.29%
Merck & Co Newsroom
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Merck & Co Analyst Ratings
Citic Securities Initiates Merck & Co. at Buy With $136 Price Target
Cantor Fitzgerald Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $155
Jefferies Adjusts Merck & Company Price Target to $147 From $150
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $150
Deutsche Bank Adjusts Price Target on Merck to $145 From $140
Daiwa Securities Adjusts Merck & Company Price Target to $130 From $150, Maintains Outperform Rating
Merck KGaA Gets a Buy From Deutsche Bank
Goldman Sachs Maintains Merck & Co(MRK.US) With Buy Rating
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Argus Research Maintains Merck & Co(MRK.US) With Buy Rating
Buy Rating Affirmed for Merck & Co. on Strong Growth Prospects Despite Gardasil's China Hurdles
Merck Price Target Cut to $145.00/Share From $150.00 by B of A Securities
Merck & Co Analyst Ratings
UBS Maintains Buy on Merck & Co, Lowers Price Target to $142
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Cuts Target Price to $130
Evercore Maintains Merck & Co(MRK.US) With Buy Rating
BofA Securities Initiates Merck & Co(MRK.US) With Buy Rating
A Quick Look at Today's Ratings for Merck & Co(MRK.US), With a Forecast Between $125 to $150